INHIBRX BIOSCIENCES, INC. Operating Expenses
INHIBRX BIOSCIENCES, INC. (INBX) reported Operating Expenses of $32.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. operating expenses for the quarter ending 2026-06-30 was $32.15M, a 12.06% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. operating expenses for the quarter ending 2026-03-31 was $30.93M, a 27.91% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. operating expenses for the quarter ending 2025-12-31 was $30.92M, a 38.19% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. operating expenses for the quarter ending 2025-09-30 was $33.81M, a 27.75% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. operating expenses for fiscal 2025 was $136.32M, a 58.89% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. operating expenses for fiscal 2024 was $331.65M, a 50.05% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. operating expenses for fiscal 2023 was $221.02M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.15M 10-Q · filed 2026-08-13 | $63.08M 10-Q · filed 2026-08-13 | $94.00M derived: sum of 3 quarters · filed 2026-08-13 | $127.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $30.93M 10-Q · filed 2026-05-14 | $61.85M derived: sum of 2 quarters · filed 2026-05-14 | $95.66M derived: sum of 3 quarters · filed 2026-05-14 | $124.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $30.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $64.73M derived: sum of 2 quarters · filed 2026-03-19 | $93.42M derived: sum of 3 quarters · filed 2026-08-13 | $136.32M 10-K · filed 2026-03-19 |
| 2025-09-30 | $33.81M 10-Q · filed 2025-11-14 | $62.50M derived: sum of 2 quarters · filed 2026-08-13 | $105.40M 10-Q · filed 2025-11-14 | $155.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $28.69M 10-Q · filed 2026-08-13 | $71.59M 10-Q · filed 2026-08-13 | $121.62M derived: sum of 3 quarters · filed 2026-08-13 | $168.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $42.90M 10-Q · filed 2026-05-14 | $92.93M derived: sum of 2 quarters · filed 2026-05-14 | $139.73M derived: sum of 3 quarters · filed 2026-05-14 | $300.72M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $50.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $96.83M derived: sum of 2 quarters · filed 2026-03-19 | $257.82M derived: sum of 3 quarters · filed 2026-03-19 | $331.65M 10-K · filed 2026-03-19 |
| 2024-09-30 | $46.80M 10-Q · filed 2025-11-14 | $207.79M derived: sum of 2 quarters · filed 2025-11-14 | $281.62M 10-Q · filed 2025-11-14 | $371.54M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $161.00M 10-Q · filed 2025-08-13 | $234.82M 10-Q · filed 2025-08-13 | $324.75M derived: sum of 3 quarters · filed 2025-08-13 | $370.69M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $73.83M 10-Q · filed 2025-05-14 | $163.75M derived: sum of 2 quarters · filed 2025-05-14 | $209.69M derived: sum of 3 quarters · filed 2025-05-14 | $251.06M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $89.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $135.87M derived: sum of 2 quarters · filed 2025-03-17 | $177.24M derived: sum of 3 quarters · filed 2025-03-17 | $221.02M 10-K · filed 2025-03-17 |
| 2023-09-30 | $45.95M 10-Q · filed 2024-11-14 | $87.31M derived: sum of 2 quarters · filed 2024-11-14 | $131.10M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $41.37M 10-Q · filed 2024-08-13 | $85.15M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |